A randomized controlled clinical study on the efficacy and safety of erbium laser percutaneous methotrexate in the treatment of localized scleroderma

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000031572

Enrollment

Unknown

Registered

2020-04-04

Start date

2020-05-01

Completion date

Unknown

Last updated

2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

morphea

Interventions

control group:Erbium laser

experimental group:erbium laser assisted delivery of methotrexate

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the diagnostic criteria for localized scleroderma (European Association of Dermatology and venereal diseases, 2017); 2. Patients who have been initially diagnosed or stopped systematic drug treatment external drug treatment for more than 2 weeks; 3. Patients aged 18 to 65 years; 4. Patients willing to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with contraindications of laser therapy: Patients with photosensitivity, skin cancer history, etc; 2. Patients with contraindications of MTX use: allergic to MTX, immunosuppressive state, abnormal liver and kidney function, etc; 3. Pregnant women or women of childbearing age who plan to be pregnant during lactation or study; 4. Mental patients who were unable to complete the study.

Design outcomes

Primary

Measure	Time frame
dermal thickness;	—

Countries

China

Contacts

Public ContactGuo Qing

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

guoqingzsy@163.com+86 18922182868

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026